Literature DB >> 3524434

Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults.

F Rogerie, D Ott, J Vandepitte, L Verbist, P Lemmens, I Habiyaremye.   

Abstract

A severe epidemic of dysentery began late in 1979 in northeast Zaire and spread to Rwanda, Burundi, and Tanzania. The epidemic strain is a multiply resistant Shigella dysenteriae type 1, which acquired resistance against trimethoprim and more recently against nalidixic acid in the course of the epidemic. A comparative open trial in Rwandan adults with Shiga dysentery involved 18 patients treated with norfloxacin at 400 mg twice daily and 12 patients treated with nalidixic acid at 1 g three times daily for 5 days. All isolates showed in vitro susceptibility to both drugs. Though norfloxacin eliminated Shigella organisms from stools more rapidly than nalidixic acid, its clinical superiority did not reach the level of significance. Norfloxacin is a promising drug and is more effective than nalidixic acid in the treatment of multiresistant shigellosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3524434      PMCID: PMC284172          DOI: 10.1128/AAC.29.5.883

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Comparative efficacy of nalidixic acid and ampicillin for severe shigellosis.

Authors:  K C Haltalin; J D Nelson; H T Kusmiesz
Journal:  Arch Dis Child       Date:  1973-04       Impact factor: 3.791

2.  Multiple transmissible drug resistance in an outbreak of Shigella flexneri infection.

Authors:  M J Lewis
Journal:  Lancet       Date:  1967-11-04       Impact factor: 79.321

3.  Treatment of sonne dysentery.

Authors:  P J Moorhead; H E Parry
Journal:  Br Med J       Date:  1965-10-16

4.  Shigella and Salmonella species from Kigali (Rwanda) (1976-1982).

Authors:  J Bogaerts; E Bosmans; L Vandenbulcke; P Lemmens; P Lepage; J Vandepitte; G Ghysels
Journal:  Ann Soc Belg Med Trop       Date:  1985-09

5.  Resistant Shigella dysenteriae.

Authors:  B R Panhotra; B Desai
Journal:  Lancet       Date:  1983-12-17       Impact factor: 79.321

6.  Nalidixic acid for shigellosis.

Authors:  H E Parry
Journal:  Lancet       Date:  1983-11-19       Impact factor: 79.321

7.  Plasmid characterisation in the investigation of an epidemic caused by multiply resistant Shigella dysenteriae type 1 in Central Africa.

Authors:  J A Frost; B Rowe; J Vandepitte; E J Threlfall
Journal:  Lancet       Date:  1981-11-14       Impact factor: 79.321

8.  Outbreak of Shigella dysentery in Eastern Zaire, 1980-1982.

Authors:  M Malengreau; M Gillieaux; M de Feyter
Journal:  Ann Soc Belg Med Trop       Date:  1983-03

9.  Comparative in vitro activities of ten antimicrobial agents against bacterial enteropathogens.

Authors:  J R Carlson; S A Thornton; H L DuPont; A H West; J J Mathewson
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

10.  Controlled comparison of nalidixic acid or lactulose with placebo in shigellosis.

Authors:  H B Hansson; G Barkenius; S Cronberg; I Juhlin
Journal:  Scand J Infect Dis       Date:  1981
View more
  15 in total

1.  In vitro activity and mode of action of fluoroquinolones.

Authors:  L Verbist
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

2.  Problems in identification of Campylobacter jejuni associated with acquisition of resistance to nalidixic acid.

Authors:  M Altwegg; A Burnens; J Zollinger-Iten; J L Penner
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

Review 3.  Antibiotic therapy for Shigella dysentery.

Authors:  Prince Rh Christopher; Kirubah V David; Sushil M John; Venkatesan Sankarapandian
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

4.  Susceptibilities of Hong Kong isolates of multiply resistant Shigella spp. to 25 antimicrobial agents, including ampicillin plus sulbactam and new 4-quinolones.

Authors:  J Ling; K M Kam; A W Lam; G L French
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

Review 5.  Transferable Mechanisms of Quinolone Resistance from 1998 Onward.

Authors:  Joaquim Ruiz
Journal:  Clin Microbiol Rev       Date:  2019-08-14       Impact factor: 26.132

Review 6.  Quinolones in the treatment of acute bacterial diarrhoeal diseases.

Authors:  H E Akalin
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  Acute bacterial diarrhoea in the emergency room: therapeutic implications of stool culture results.

Authors:  N Kaminski; V Bogomolski; R Stalnikowicz
Journal:  J Accid Emerg Med       Date:  1994-09

8.  A look back at an ongoing problem: Shigella dysenteriae type 1 epidemics in refugee settings in Central Africa (1993-1995).

Authors:  Solen Kernéis; Philippe J Guerin; Lorenz von Seidlein; Dominique Legros; Rebecca F Grais
Journal:  PLoS One       Date:  2009-02-13       Impact factor: 3.240

Review 9.  The new quinolones in the treatment of diarrhoea and typhoid fever.

Authors:  A Waiz
Journal:  Drugs       Date:  1995       Impact factor: 9.546

10.  High level resistance to trimethoprim, cotrimoxazole and other antimicrobial agents among clinical isolates of Shigella species in Ontario, Canada--an update.

Authors:  N Harnett
Journal:  Epidemiol Infect       Date:  1992-12       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.